Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine ± homoharringtonine in newly diagnosed elderly AML
ChiCTR2600122940Phase 3Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, azacitidine and homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Composite Complete Remission Rate (CRc) before start of 4th cycle. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
venetoclaxazacitidinehomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600122940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122940.